• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Meiqian,LIANG Yanni,ZHANG Yixuan,XU Sheng,XIN Qiaoyi,SUN Yu,ZHOU Jing.Integrating transcriptomics with molecular docking to predict the multi-target mechanism of hydnocarpin D against colorectal cancer[J].Journal Of Pharmaceutical Research,2026,45(4):388-394[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2217times   Download 1088次 QR Code for this article
Scan with your phone!
整合转录组学与分子对接预测次大风子素抗结直肠癌的多靶点机制
张玫倩1,梁艳妮2,张艺萱3,徐胜3,辛乔艺3,孙驭4,周静3
Font:Larger+|Default|Smaller-
(1.陕西中医药大学基础医学院,陕西 咸阳 712046;2.陕西中药资源产业化省部共建协同创新中心,陕西 咸阳 712083;3.陕西中医药大学药学院,陕西 咸阳 712046;4.陕西中医药大学中西医结合学院,陕西 咸阳 712046)
摘要:
目的 探讨次大风子素对结直肠癌细胞的抑制作用及其潜在机制。方法 采用 CCK-8法检测其对HCT116、HepG2 和 SGC7901细胞增殖的影响;对处理后的HCT116细胞进行RNA-seq,结合基因本体/京都基因与基因组百科全书(GO/KEGG)富集、蛋白-蛋白相互作用(PPI)网络分析筛选关键基因,并通过分子对接验证作用靶点。结果 次大风子素对3种细胞呈浓度依赖性抑制,其中HCT116最敏感(IC50=13.02 μmol·L-1)。共鉴定2 599 个差异基因,主要富集于p53、PI3K-Akt通路及核糖体功能。分子对接显示其与KRAS、caspase-9、GSK3β具有较强结合能力。结论 次大风子素可能通过多靶点协同调控肿瘤相关通路发挥抗结直肠癌作用,具有进一步研究价值。
关键词:  次大风子素  结直肠癌  转录组学  p53信号通路  分子对接
DOI:10.13506/j.cnki.jpr.2026.04.005
基金项目:陕西省教育厅青年创新团队项目(No.24JP047);陕西省科技厅科技计划项目(No.2024JC-YBQN-0945);陕西省教育厅科学研究计划项目(No.23JK0405);陕西省大学生创新训练计划项目(No.S202410716057)
Received Date:November 18, 2025   Revision Date:December 22, 2025   Publication Date:April 30, 2026
Integrating transcriptomics with molecular docking to predict the multi-target mechanism of hydnocarpin D against colorectal cancer
ZHANG Meiqian1,LIANG Yanni2,ZHANG Yixuan3,XU Sheng3,XIN Qiaoyi3,SUN Yu4,ZHOU Jing3
(1.College of Basic Medical,Shaanxi University of Chinese Medicine,Xianyang 712046,China;2.Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization,Shaanxi University of Chinese Medicine,Xianyang 712083,China;3.College of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,China;4.School of Integrated Chinese and Western Medicine,Shaanxi University of Chinese Medicine,Xianyang 712046,China)
Abstract:
Objective To investigate the inhibitory effects of hydnocarpin D on colorectal cancer cells and elucidate its potential mechanisms.Methods Cell viability of HCT116, HepG2, and SGC7901 cells was assessed using the CCK-8 assay. RNA sequencing of hydnocarpin D-treated HCT116 cells was performed to identify differentially expressed genes (DEGs), followed by GO/KEGG enrichment and protein-protein interaction (PPI) analyses. Molecular docking was conducted to evaluate the binding affinity between hydnocarpin D and candidate targets.Results Hydnocarpin D inhibited cell proliferation in a dose-dependent manner, with HCT116 cells being the most sensitive (IC50=13.02 μmol·L-1). A total of 2 599 DEGs were identified, mainly enriched in the p53 signaling pathway, PI3K-Akt pathway, and ribosome biogenesis. Docking analysis revealed stable interactions between Hydnocarpin D and KRAS, caspase-9, and GSK3β. Conclusion Hydnocarpin D may exert anti-colorectal cancer effects through multi-target modulation of tumor-related signaling pathways, supporting its potential as a candidate anticancer compound.
Key words:  Hydnocarpin D  Colorectal cancer  Transcriptomics  p53 signaling  Molecular docking
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.